What Happened

Disc Medicine presented updated Phase 2 clinical data at the 2026 EHA meeting. The data showed meaningful anemia responses for DISC-0974 in myelofibrosis and sustained PPIX reductions for bitopertin in EPP, along with improved light tolerance.

Who Is Affected

Patients suffering from myelofibrosis anemia and erythropoietic protoporphyria (EPP) are directly impacted by these clinical advancements. Hematologists and oncologists treating these conditions will also be interested in the potential new treatment options.

Market Impact

• Disc Medicine's stock gained 1.23% with below-average volume.
• Mixed reactions from recent news suggest company-specific movements rather than broad sector rotation.
• Investors may focus on the durability of responses and safety over 2.5+ years.

What to Watch

Key upcoming events include End-of-Phase 2 FDA discussions for DISC-0974 in 2026, Phase 3 APOLLO readout for bitopertin in Q4 2026, and initial Phase 2 RESTORE-PV data for DISC-3405 in Q4 2026. These milestones could significantly impact Disc Medicine's pipeline and market position.